1.Network meta-analysis for efficacy and safety of aromatase inhibitors for postmenopausal hormone receptor-positive early breast cancer
Yujie LI ; Wenjing ZHANG ; Hongxin YANG ; Hao GUO
China Pharmacy 2025;36(12):1520-1524
OBJECTIVE To evaluate the efficacy and safety of three aromatase inhibitors (exemestane, anastrozole, letrozole) for postmenopausal hormone receptor (HR)-positive early breast cancer. METHODS PubMed, the Cochrane Library, Embase, CNKI, Wanfang Data, VIP and SinoMed were searched to collect randomized controlled trials (RCTs) of the above three drugs in the treatment of postmenopausal HR-positive early breast cancer patients. The retrieval time limit was from the establishment of the database to October 25, 2024. After literature screening, data extraction and literature quality evaluation, network meta-analysis was performed by using RevMan 5.3 and Stata 18.0 software. RESULTS A total of 15 RCTs involving 44 055 patients were included. The results of network meta-analysis showed that the objective response rate of letrozole group was significantly higher than anastrozole group (P<0.05), and the order of surface under the cumulative ranking curve (SUCRA) from high to low was letrozole (85.6%)>anastrozole (61.5%)>exemestane (2.8%). The disease-free survival rate of anastrozole group was significantly higher than exemestane and placebo groups (P<0.05), and the order of SUCRA from high to low was letrozole (85.8%)> anastrozole (67.3%)>exemestane (41.4%)>placebo (5.5%). The total incidence of adverse reactions in anastrozole group was significantly higher than letrozole and placebo groups (P<0.05), and the order of SUCRA from high to low was exemestane (87.4%)>letrozole (63.9%)>anastrozole (47.0%)>placebo (1.7%). The results of subgroup analysis according to the course of treatment≥104 weeks were consistent with them. CONCLUSIONS Compared with anastrozole, letrozole has better efficacy and safety in the treatment of postmenopausal HR-positive early breast cancer, and the efficacy of exemestane is limited.
2.Screening and experimental validation of hub genes for myocardial isch-emia-reperfusion injury based on bioinformatics
Jianru WANG ; Xingyuan LI ; Shiyang XIE ; Yanling CHENG ; Hongxin GUO ; Mingjun ZHU ; Rui YU
Chinese Journal of Pathophysiology 2024;40(3):473-483
AIM:Using bioinformatics analysis methods to identify the hub genes involved in myocardial isch-emia-reperfusion injury(MIRI).METHODS:Firstly,the rat MIRI related dataset GSE122020,E-MEXP-2098,and E-GEOD-4105 were downloaded from the database.Secondly,differentially expressed genes(DEGs)were screened from each dataset using the linear models for microarray data(limma)package,and robust DEGs were filtered using the robust rank aggregation(RRA)method.In addition,the surrogate variable analysis(SVA)package was used to merge all datas-ets into one,and merged DEGs were screened using the limma package.The common DEGs were obtained by taking the intersection of the two channels of DEGs.Next,the protein-protein interaction(PPI)network of common DEGs was con-structed,and the hub genes were identified using the density-maximizing neighborhood component(DMNC)algorithm.The receiver operating characteristic curve(ROC)was plotted to evaluate the diagnostic performance of the hub gene.Then,the mRNA and protein expression levels of hub genes were detected in the rat MIRI model,and the literature re-view analysis was carried out on the involvement of hub genes in MIRI.Finally,the gene set enrichment analysis(GSEA)was performed on hub gene to further reveal the possible mechanism in mediating MIRI.RESULTS:A total of 143 robust DEGs and 48 merged DEGs were identified.After taking the intersection of the two,48 common DEGs were obtained.In the PPI network of common DEGs,5 hub genes were screened out,namely MYC proto-oncogene bHLH transcription fac-tor(MYC),prostaglandin-endoperoxide synthase 2(PTGS2),heme oxygenase 1(HMOX1),caspase-3(CASP3),and plasminogen activator urokinase receptor(PLAUR).The ROC results showed that the area under the curve values for all hub genes were greater than 0.8.MYC,PTGS2,CASP3,and PLAUR showed high mRNA and protein expression in rat MIRI,while there was no difference in mRNA and protein expression for HMOX1.The literature review revealed that among the 5 hub genes,only PLAUR has not been reported to be involved in MIRI.The GSEA results for PLAUR indicat-ed that its functional enrichment mainly focused on pathways such as NOD-like receptor signaling pathway,P53 signaling pathway,Toll-like receptor signaling pathway,apoptosis,and fatty acid metabolism.CONCLUSION:MYC,PTGS2,CASP3,HMOX1,and PLAUR are involved in the pathological process of MIRI.PLAUR is a potential hub gene that can mediate MIRI by regulating pathways such as NOD like receptor signaling,P53 signaling,Toll like receptor signaling,cell apoptosis,and fatty acid metabolism.The results can provide reference for further investigation into the molecular mechanisms and therapeutic targets of MIRI.
3.A Cross-Sectional Study of Secondary Prevention Status and Influencing Factors of Stable Angina in 1061 Patients with Coronary Heart Disease
Rui YU ; Yingqiang ZHAO ; Peng LI ; Jianru WANG ; Xinlu WANG ; Qifei ZHAO ; Yuan GAO ; Hongxin GUO ; Mingjun ZHU
Journal of Traditional Chinese Medicine 2024;65(20):2126-2134
ObjectiveTo investigate the current status of secondary prevention of stable angina in patients with coronary heart disease in three regions of China, namely Henan Province, Xinjiang Uygur Autonomous Region, and Tianjin City, and analyze the the influencing factors. MethodsA cross-sectional study was conducted to include patients with stable angina with coronary heart disease in Henan, Tianjin and Xinjiang from August 10, 2020 to March 14, 2021. General information, traditional Chinese medicine (TCM) syndrome elements, prescriptions and other data of patients were collected, and clinical characteristics, blood pressure, blood lipid and blood glucose of patients were analyzed; the patients were divided into groups according to whether their blood pressure, blood lipid and blood glucose were up to standard. With the most common syndrome element as the main variable, region, age and gender as covariables, Logistic regression equation was incorporated to analyze the influencing factors for the patients' blood pressure, blood lipid and blood glucose being up to standard. ResultsA total of 1061 coronary heart disease patients with stable angina were included, including 658 in Henan, 210 in Xinjiang, and 193 in Tianjin. The clinical characteristics of patients in the three regions showed statistical different in age, sex, disease course, complication, blood pressure, blood lipid, blood glucose, smoking, drinking, living habits, and medication treatment (P<0.05 or P<0.01). For the included patients, qi deficiency (79.55%, 844/1061) and blood stasis (39.96%, 424/1061) were the main syndrome elements. The overall compliance rate of blood pressure was 48.89% (506/1035), blood lipids 12.68% (133/1049) and blood glucose 48.18% (504/1046). Qi deficiency was the independent factor affecting the blood pressure of coronary heart disease patients with stable angina combined with hypertension (P = 0.029,95%CI [1.048, 2.369]), and the independent factors influencing the blood lipid standard of coronary heart disease patients with stable angina (P = 0.011, 95%CI [1.133, 2.646]), but not the independent factors affecting blood glucose standard in coronary heart disease patients with diabetes (P>0.05). ConclusionCoronary artery disease patients with stable angina have geographical variability in clinical characteristics and distribution of TCM syndrome elements, and the overall control of blood pressure, blood lipids, and blood glucose is poor, and qi deficiency syndrome is an independent risk factor affecting the control of blood pressure and blood lipids.
4.Effectiveness of TCM Health Management for Myocardial Infarction based on Tertiary Management System: A Single-arm Cohort Study of 255 Patients
Hongxin GUO ; Mingjun ZHU ; Rui YU ; Xingyuan LI ; Guangcao PENG ; Xinlu WANG ; Jianru WANG ; Bin LI ; Qifei ZHAO ; Yongxia WANG
Journal of Traditional Chinese Medicine 2024;65(8):821-829
ObjectiveTo evaluate the efficacy of TCM health management based on tertiary management system for patients with myocardial infarction (MI). MethodsA total of 277 patients with non-acute MI were enrolled and given comprehensive TCM health management strategies including health education, lifestyle adjustment, risk factors control, medication and TCM appropriate techniques management through a tertiary management system with "the patient as the core, village/community physicians as the main executive body, and tertiary TCM hospital specialists as the leading body", for a period of 12 months by using a prospective single-arm cohort study. Through patient reporting and medical records surveys, various indicators before and after 12-month management were collected and compared. The primary efficacy indicators were readmission rate and recurrent exacerbation rate, and the secondary efficacy indicators included disease awareness-related indicators, lifestyle behavior-related indicators, cardiovascular risk factor-related indicators and Canadian cardiovascular society (CCS) cardiac function classification. ResultsA total of 255 patients completed the study and were included in the final analysis. The recurrent exacerbation and readmission rates of patients after management were 23.14% (59 cases) and 20.25% (49 cases), respectively, significantly lower than 36.08% (92 cases) and 53.72% (130 cases) before management (P<0.05). Except for knowledge on diabetes diagnostic criteria with no significant difference before and after management (P>0.05), awareness of other knowledge with regard to the prevention and treatment of cardiovascular and cerebrovascular diseases were improved after management (P<0.01), as well as the total score (P<0.01). In terms of daily life behaviors, the rates of salty diet, sweet diet and greasy diet were significantly lower than baseline, while the rate of moderate exercise was significantly higher (P<0.05 or P<0.01); the rates of ongoing smoking and vigorous exercise were not significantly changed (P>0.05). For cardiovascular risk factors, patients' total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, fasting glucose, total depression assessment scale score, and total anxiety assessment scale score were significantly reduced after management (P<0.01). Systolic blood pressure and body mass index (BMI) were both higher after management (P<0.05 or P<0.01), and there was no statistically significant difference in diastolic blood pressure (P>0.05). In terms of the cardiovascular disease risk factors reaching the standard levels, the rate of LDL cholesterol <1.8 mmol/L significantly increased (P<0.01), while the rate of BMI <24 kg/m2 and the rate of systolic blood pressure <140 mmHg both decreased significantly (P<0.05 or P<0.01) from baseline; the diastolic blood pressure and rate of fasting glucose <7.0 mmol/L were not significantly changed (P>0.05). The patients' CCS cardiac function classification was significantly reduced (P<0.05). ConclusionTCM health management based on the tertiary management system can enhance MI patients' awareness of the disease, change poor lifestyle habits, reduce risk factors such as blood lipids and blood glucose, improve anxiety and depression, increase activity tolerance, and reduce their recurrence exacerbation and readmission rates, which is worthy of clinical promotion.
5.Research advances in liver cancer organoids
Li ZHAO ; Ziqi GUO ; Yong YANG ; Hongxin YANG
Journal of Clinical Hepatology 2024;40(7):1486-1492
Organoids are a novel disease model that is self-assembled from stem cells or malignant tumors and is used in clinical research.They are similar to tissues and organs in the body and have partially functional 3D cell structures.There are two types of traditional models for liver cancer research,i.e.,in vivo models(animal models of liver cancer established by induction)and in vitro cell experiments using corresponding cell lines.Organoids have the advantages of the two types of traditional models and show unique advantages in tumor research.Traditional models cannot fully reflect the microenvironment of cells,which often leads to the inconsistency with clinical research findings,and the emergence of new research models provides a new direction for the research on liver cancer.This article reviews the research advances in liver cancer organoids,in order to provide a new perspective for future research on liver cancer.
6.Exploration on "Symptom-Syndrome-Drug" Regularity of Traditional Chinese Medicine for Coronary Microvascular Disease Based on Latent Structure Combined with Association Rules
Yilin ZHANG ; Jingjing WEI ; Hongxin GUO ; Lele HUO ; Mingjie ZHANG ; Jianfeng LU ; Aolong WANG ; Mingjun ZHU
Traditional Chinese Drug Research & Clinical Pharmacology 2024;35(5):730-740
Objective To systematically explore the traditional Chinese medicine(TCM)common symptoms,syndrome elements,clinical syndrome differentiation,and medication rules of coronary microvascular disease(CMVD),and to provide a reference for quantitative criteria of clinical differentiation of CMVD,specification of the diagnosis and efficacy evaluation of TCM clinical syndrome,and guidance of clinical medication.Methods The databases including CNKI,Wanfang,VIP,and SinoMed were searched for research papers on the treatment of CMVD by TCM published from database inception to May 16,2023.Relevant information of the included literature was extracted and the database was established.Then,the frequency statistics of symptoms,syndrome elements,syndrome types and Chinese medicinals were carried out.Latent structural models were constructed using Latern 5.0 and Rstudio softwares respectively for comprehensive clustering and association rule analysis,so as to explore the symptom characteristics,syndrome elements distribution,common syndromes and medication rules for TCM treatment of CMVD.Results A total of 107 literature were included,involving 36 syndromes,17 syndrome elements,121 symptoms and 143 Chinese medicinals.It was speculated that the main syndrome element of CMVD was blood stasis,followed by qi deficiency,qi stagnation,phlegm turbidity,yin deficiency and yang deficiency.The main type of syndrome was qi deficiency and blood stasis,followed by heart blood stasis obstruction,qi stagnation and blood stasis,phlegm blended with stasis,qi-yin deficiency,etc..The main medicinals were Chuanxiong Rhizoma,Salviae Miltiorrhizae Radix et Rhizoma,Angelica Sinensis Radix and Astragali Radix.The medicinals used in the treatment of CMVD were classified as blood-activating and stasis-resolving drugs,deficiency-tonifying drugs,qi-regulating drugs in terms of their efficacy.Conclusion The location of CMVD is in heart,and related to liver and kidney.The syndrome of CMVD is deficiency in origin and excess in superficiality.Blood stasis runs through the development of the disease.The treatment is mainly to activate blood circulation and remove stasis,activate meridians and relieve pain,which should be supplemented with the therapies of tonifying and invigorating qi,soothing the liver and regulating qi,dispelling phlegm and dissipating masses according to the patients'syndromes.
7.A phase Ⅱ clinical study of the efficacy and safety of antaitasvir phosphate combined with yiqibuvir for the treatment of chronic hepatitis C in adults
Lai WEI ; Hongxin PIAO ; Jinglan JIN ; Shufen YUAN ; Xuan AN ; Jia SHANG ; Wenhua ZHANG ; Jiabao CHANG ; Tong SUN ; Yujuan GUAN ; Bo NING ; Jing ZHU ; Wentao GUO ; Qingwei HE ; Lin LUO ; Yulei ZHUANG ; Hongming XIE ; Yingjun ZHANG
Chinese Journal of Hepatology 2024;32(7):637-642
Objective:To evaluate the efficacy and safety of antaitasvir phosphate 100 mg or 200 mg combined with yiqibuvir for 12 weeks in patients with various genotypes of chronic hepatitis C, without cirrhosis or compensated stage cirrhosis.Methods:Patients with chronic hepatitis C (without cirrhosis or compensated stage cirrhosis) were randomly assigned to the antaitasvir phosphate 100 mg+yiqibuvir 600 mg group (100 mg group) or the antaitasvir phosphate 200 mg+yiqibuvir 600 mg group (200 mg group) in a 1∶1 ratio. The drugs were continuously administered once a day for 12 weeks and observed for 24 weeks after drug withdrawal. The drug safety profile was assessed concurrently with the observation of the sustained virological response (SVR12) in the two patient groups 12 weeks following the drug cessation. The intention-to-treat concept was used to define as closely as possible a full analysis set, including all randomized cases who received the experimental drug at least once. The safety set was collected from all subjects who received the experimental drug at least once (regardless of whether they participated in the randomization group) in this study. All efficacy endpoints and safety profile data were summarized using descriptive statistics. The primary efficacy endpoint was SVR12. The primary analysis was performed on a full analysis set. The frequency and proportion of cases were calculated in the experimental drug group (antaitasvir phosphate capsules combined with yiqibuvir tablets) that achieved "HCV RNA
8.A Data Mining-Based Study on the Medication Rules of Chinese Medicine to Treat Heart Failure with Diuretic Resistance
Hongxin GUO ; Bin LI ; Haifeng YAN ; Xingyuan LI ; Mingjun ZHU
World Science and Technology-Modernization of Traditional Chinese Medicine 2023;25(9):3063-3070
Objective To explore the medication rules of clinical prescriptions of Chinese medicine in the treatment of heart failure with diuretic resistance based on data mining method.Methods Seven domestic and foreign databases,including CNKI and Wanfang,were searched for literature on Chinese medicine for heart failure with diuretic resistance from the establishment of the database to October 2021.Frequency analysis,association rule analysis and cluster analysis were used for statistical analysis.Results A total of 41 literatures were included,including 39 prescriptions.Yang deficiency and water retention were the main symptoms of the disease.A total of 72 single herbs were used,with a total of 438 times of use.There are 30 Chinese medicines with a frequency of more than 5 times,involving 9 efficacy categories,mainly tonic medicines,diuresis and dampness medicines,blood-activating and stasis-removing medicines,and interior-warming medicines.The association rule analysis yielded drug compatibility with Poria as the core,such as Atractylodis Macrocephalae Rhizoma→Poria and Cinnamomi Ramulus→Poria.Cluster analysis yielded six new formula combinations with efficacy in warming Yang,inducing diuresis,benefiting qi and invigorating Blood.Conclusion Heart failure with diuretic resistance is a syndrome of root vacuity and tip repletion,cold-heat complex,and the core pathogenesis is"deficiency","water"and"stasis".The treatment of this disease occurs by warming yang and excreting water,supplemented by replenishing qi and activating blood circulation.Poria with Atractylodis Macrocephalae Rhizoma and Cinnamomi Ramulus are commonly used combinations,and Zhen Wu Decoction is the basic formula for the treatment of this disease.
9.Meta-analysis of the Effectiveness and Safety of Compound Danshen Dripping Pills in Improving Aspirin Resistance
Hongxin GUO ; Lijie QIAO ; Jingjing WEI ; Rui YU ; Bin LI ; Guangcao PENG ; Yongxia WANG ; Mingjun ZHU
China Pharmacy 2021;32(6):743-749
OBJECTIVE:To systematically evaluate the effectiveness and safety of Compound danshen dripping pills in improving aspirin resistance ,and to provide evidence-based evidence for clinical drug use. METHODS :Retrieved from CNKI , VIP,Wanfang database ,CBM,PubMed,Embase,the Cochrane L ibrary,randomized controlled trials (RCTs)about Compound danshen dripping pills (trial group )versus aspirin (control group )were collected during the inception to Jun. 2020. After literature screening and data extraction ,bias risk assessment tool recommended by the Cochrane evaluation manual handbook 5.1.0 was used to evaluate the quality of the included literatures ,and Rev Man 5.3 software was used for Meta-analysis and publication bias analysis. RESULTS :A total of 10 RCTs were included ,with a total of 800 patients. Meta-analysis showed that the platelet aggregation rate (PAR)induced by adenosine diphosphate (ADP)in trial group was significantly lower than that of control group [SMD =-2.63,95%CI(-3.56,-1.70),P<0.000 01]. Results of sub-group analysis by treatment cycle showed that PAR induced by ADP in trial group after 2 weeks of treatment [SMD =-2.11,95%CI(-2.75,-1.46),P<0.000 01],4 weeks of treatment [SMD =-2.84,95%CI(-4.26,-1.41),P<0.000 1] Δ 基金项目 :国家重点研发计划中医药现代化研究重点专项 and 8 weeks of treatment [SMD =-2.63,95%CI(-3.21, (No.2019YFC1710000,No.2019YFC1710003);国家中医药管理局中 - 2.04),P<0.000 01] was significantly lower than control 医药循证能力建设项目(No.2019XZZX-XXG003);河南省创新型科技 团队项目 group. PAR induced by arachidonic acid (AA)of trial group *硕士研究生 。研究方向:中西医结合心血管疾病的预防和治 was significantly lower than that of control group [SMD = 疗。E-mail:guohongxin1214@163.com -2.44,95%CI(-3.64,-1.24),P<0.000 1]. Results of # 通信作者:主任医师,教授,硕士生导师,博士。研究方向:中医 sub-group analysis by treatment cycle showed that PAR 药防治心血管疾病的临床和基础 。电话:0371-66233478。E-mail: induced by AA in trial group after 2 weeks of tre atment [SMD = zhumingjun317@163.com -2.56,95%CI(-3.26,-1.85),P<0.000 01],4 weeks of 中国药房 2021年第32卷第6期 China Pharmacy 2021Vol. 32 No. 6 ·743· treatment of [SMD =-2.45,95%CI(-4.79,-0.10),P=0.04],8 weeks of treatment [SMD =-2.38,95%CI(-2.94,-1.82),P< 0.000 01] was significantly lower than control group. The decrease of ADP-induced PAR [SMD =2.24,95%CI(1.36,3.13),P< 0.000 01],AA-induced PAR [SMD =2.42,95%CI(1.94,2.89),P<0.000 01] and response rate [RR =8.56,95%CI(4.38,16.74), P<0.000 01] in trial group were significantly higher than control group ,while the incidence of ADR [RR =0.30,95%CI(0.15, 0.60),P=0.000 6],the incidence of ischemic events [RR =0.13,95%CI(0.07,0.27),P<0.000 01],CR and RF after treatment (P<0.05)were significantly lower than control group. There was no statistical significant difference in the incidence of bleeding events between 2 groups [RR =0.78,95% CI(0.34,1.78),P=0.55]. The results of publication bias showed that there was less possibility of publication bias in this study. CONCLUSIONS :Compound danshen dripping pills can effectively improve aspirin resistance and has good safety.
10.Efficacy of percutaneous intervention for patent ductus arteriosus guided by transesophageal echocardiography in obese teenagers
Ning WANG ; Ping WEN ; Yuhang LIU ; Minglei GAO ; Dawei LIU ; Wenbin GUO ; Hongxin LI
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2020;27(05):521-524
Objective To explore the safety and efficacy of transesophageal echocardiography (TEE)-guided percutaneous intervention for patent ductus arteriosus (PDA) in obese teenagers. Methods From January 2018 to June 2019, 21 obese teenagers with PDA treated with femoral artery occlusion guided by TEE in the Department of Cardiac Surgery, Dalian Children's Hospital of Dalian Medical University were included in this study, including 13 males and 8 females aged 12.8-17.3 (15.1±1.7) years, with an average weight of 51.0-89.0 (73.4±10.1) kg. The operative effect was evaluated. Results All patients successfully received the surgery, and none was changed to radiation-guided or thoracotomy ligation. The average operating time was 23.9±6.8 min, the average postoperative hospitalization time was 3.8±0.6 d. No peripheral vascular injury, intracardiac infection or pericardial effusion occurred. The mean follow-up time was 19.5±4.9 months, and the results of all reexaminations were good. Conclusion For some PDA children with obesity, emphysema or thoracic malformation, it is difficult to block PDA by transthoracic ultrasound-guided percutaneous intervention, and TEE can avoid the interference of chest wall and lung qi, or other factors. It is an effective supplementary guidance method worthy of promotion.

Result Analysis
Print
Save
E-mail